Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
11.944 / 17.026
#95547

Re: Farmas USA

danip, no la conocía, me la acabo de instalar porque tampoco usaba alertas. gracias por el tip

#95549

Re: Farmas USA

RDUS
Por lo que leo en ST, y viendo el premarket, parece que se re-avivan los rumores del BO de RDUS por Shire.
Shire close to deal for Radius Health
http://www.seekingalpha.com/news/3213304

#95550

Re: Farmas USA

HZNP

Otra que recorta expectativas de Q3 y de todo el año

The Company is revising its full-year 2016 adjusted EBITDA guidance range as the result of expected net sales at the low end of its non-GAAP adjusted net sales guidance range and anticipated higher investment spending in the fourth quarter of 2016 and now expects adjusted EBITDA to be in the range of $450 to $460 million (prior range was $495 to $510 million).

http://ir.horizon-pharma.com/secfiling.cfm?filingID=1193125-16-734829&CIK=1492426

De momento -5% en PM tras conocerse la noticia

#95552

Re: Farmas USA

ARNA

Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting

Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET. The meeting is taking place October 15-19 in Vienna, Austria. The data will also be published in the December issue of United European Gastroenterology Journal, a peer-reviewed medical journal providing coverage of both translational as well as clinical studies from all fields of gastroenterology.

The following abstract will be presented:

Lecture: LB20 - RECEPTOR PROFILE AND EFFICACY OF ETRASIMOD (APD334), AN ORAL, NEXT-GENERATION SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR IN DEVELOPMENT FOR ULCERATIVE COLITIS
Session: 807 - Improving therapy in IBD
Session Type: Late Breaking Abstracts
Date: Tuesday, October 18, 2016

«Después de nada, o después de todo/ supe que todo no era más que nada.»